To address the evidence gap regarding long-term outcomes of integrating molecular imaging into the evaluation paradigm for recurrent prostate cancer, we developed a decision analytic model to estimate clinical outcomes associated with PSMA-PET vs conventional imaging strategies. This evidence concerns the gene FOLH1 and Familial prostate cancer.